![Pharmaceutics | Free Full-Text | Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects Pharmaceutics | Free Full-Text | Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects](https://www.mdpi.com/pharmaceutics/pharmaceutics-14-01807/article_deploy/html/images/pharmaceutics-14-01807-g010.png)
Pharmaceutics | Free Full-Text | Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects
![Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies - Clinical Therapeutics Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies - Clinical Therapeutics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/bf9d0a08-b654-43d3-a093-b36672cae85a/gr1_lrg.jpg)
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies - Clinical Therapeutics
![Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega](https://pubs.acs.org/cms/10.1021/acsomega.1c06920/asset/images/large/ao1c06920_0006.jpeg)
Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega
![Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations - Pilla Reddy - 2019 - Clinical Pharmacology & Therapeutics - Wiley Online Library Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations - Pilla Reddy - 2019 - Clinical Pharmacology & Therapeutics - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/ae98dccf-b486-4a03-9b89-a4c9eded7cdf/cpt1103-fig-0002-m.jpg)
Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations - Pilla Reddy - 2019 - Clinical Pharmacology & Therapeutics - Wiley Online Library
![Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega](https://pubs.acs.org/cms/10.1021/acsomega.1c06920/asset/images/medium/ao1c06920_0003.gif)
Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega
![Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations - Cancer Treatment Reviews Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations - Cancer Treatment Reviews](https://www.cancertreatmentreviews.com/cms/asset/f3e3b15f-652d-476e-b830-11a8e3575b86/gr1.jpg)
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations - Cancer Treatment Reviews
![Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega](https://pubs.acs.org/cms/10.1021/acsomega.1c06920/asset/images/medium/ao1c06920_0005.gif)